PL2305221T3 - Inhibitory naprawy uszkodzeń DNA w leczeniu raka - Google Patents

Inhibitory naprawy uszkodzeń DNA w leczeniu raka

Info

Publication number
PL2305221T3
PL2305221T3 PL10178515T PL10178515T PL2305221T3 PL 2305221 T3 PL2305221 T3 PL 2305221T3 PL 10178515 T PL10178515 T PL 10178515T PL 10178515 T PL10178515 T PL 10178515T PL 2305221 T3 PL2305221 T3 PL 2305221T3
Authority
PL
Poland
Prior art keywords
treatment
cancer
dna damage
damage repair
repair inhibitors
Prior art date
Application number
PL10178515T
Other languages
English (en)
Polish (pl)
Inventor
Alan Ashworth
Stephen Jackson
Niall Martin
Graeme Smith
Original Assignee
Kudos Pharm Ltd
The Institute Of Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34655227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2305221(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0327844A external-priority patent/GB0327844D0/en
Application filed by Kudos Pharm Ltd, The Institute Of Cancer Res filed Critical Kudos Pharm Ltd
Publication of PL2305221T3 publication Critical patent/PL2305221T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10178515T 2003-12-01 2004-11-30 Inhibitory naprawy uszkodzeń DNA w leczeniu raka PL2305221T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52624403P 2003-12-01 2003-12-01
GB0327844A GB0327844D0 (en) 2003-12-01 2003-12-01 Therapeutic methods and means
EP04798705A EP1684736B1 (en) 2003-12-01 2004-11-30 Dna damage repair inhibitors for treatment of cancer
EP20100178515 EP2305221B1 (en) 2003-12-01 2004-11-30 DNA damage repair inhibitors for treatment of cancer

Publications (1)

Publication Number Publication Date
PL2305221T3 true PL2305221T3 (pl) 2015-11-30

Family

ID=34655227

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10178515T PL2305221T3 (pl) 2003-12-01 2004-11-30 Inhibitory naprawy uszkodzeń DNA w leczeniu raka
PL04798705T PL1684736T3 (pl) 2003-12-01 2004-11-30 Inhibitory naprawy DNA w leczeniu raka

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04798705T PL1684736T3 (pl) 2003-12-01 2004-11-30 Inhibitory naprawy DNA w leczeniu raka

Country Status (22)

Country Link
US (6) US8071579B2 (https=)
EP (2) EP2305221B1 (https=)
JP (2) JP5545690B2 (https=)
KR (1) KR20060123403A (https=)
CN (1) CN102107008B (https=)
AT (1) ATE521341T1 (https=)
AU (2) AU2004294790B2 (https=)
BR (1) BRPI0417056A (https=)
CA (1) CA2547077C (https=)
DK (2) DK2305221T3 (https=)
ES (2) ES2545613T3 (https=)
HU (1) HUE025996T2 (https=)
IL (1) IL176013A (https=)
MX (1) MXPA06006120A (https=)
NO (1) NO335959B1 (https=)
NZ (1) NZ547984A (https=)
PL (2) PL2305221T3 (https=)
PT (2) PT1684736E (https=)
RU (3) RU2413515C2 (https=)
SG (1) SG150548A1 (https=)
TW (1) TWI338000B (https=)
WO (1) WO2005053662A1 (https=)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
EP1603567A4 (en) 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
US7531530B2 (en) * 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
JP2008531562A (ja) 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法
CN101233121A (zh) * 2005-06-10 2008-07-30 彼帕科学公司 Parp调节剂和癌症的治疗
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
CN101316592A (zh) 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20090281086A1 (en) * 2006-06-15 2009-11-12 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
US20090181951A1 (en) * 2006-06-15 2009-07-16 Kudos Pharmaceuticals Limited Parp inhibitors
WO2007144639A1 (en) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage
CN101534836B (zh) 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
EP2092083A2 (en) 2006-10-20 2009-08-26 Dana-Farber Cancer Institute Dna damage repair inhibitors and methods for treating cancer
GB2453011B (en) * 2006-12-29 2010-06-23 Tracon Pharmaceuticals Inc Antifolate agent compositions in the treatment of cancer
KR20090115879A (ko) 2007-02-28 2009-11-09 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체와 이의 이용 방법
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20100249112A1 (en) * 2007-05-25 2010-09-30 Astrazeneca R&D Combination of chk and parp inhibitors for the treatment of cancers
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
ES2504690T3 (es) * 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
CA2702429A1 (en) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
US20100267626A1 (en) * 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
JP5436786B2 (ja) * 2008-03-06 2014-03-05 オリンパス株式会社 細胞周期計測方法
WO2010042514A1 (en) * 2008-10-06 2010-04-15 Arizona Board Of Regents Nanopore and carbon nanotube based dna sequencer and a serial recognition elements
CA2737400C (en) * 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010099526A1 (en) * 2009-02-27 2010-09-02 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
US20110015393A1 (en) * 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2322658A1 (en) 2009-11-13 2011-05-18 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of breast cancer aggressiveness and genetic instability
EP2619574B1 (en) 2010-09-15 2020-10-28 Almac Diagnostic Services Limited Molecular test for predicting responsiveness to dna-damage therapeutic agents in individuals having cancer
US9359605B2 (en) * 2011-03-11 2016-06-07 Sarissa Inc. Method of treating cancer by inhibition of DNA repair proteins
EP2710142B1 (en) 2011-05-18 2017-04-26 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of cancer aggressiveness and genetic instability
JP6270719B2 (ja) 2011-07-22 2018-01-31 パシレックス・ファーマシューティカルズ・インコーポレイテッド 合成致死性および癌の治療
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
EP2800821B1 (en) 2012-01-05 2016-11-16 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of lung cancer aggressiveness
US10220051B2 (en) 2012-03-29 2019-03-05 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
US8927516B2 (en) * 2012-03-29 2015-01-06 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
RU2492242C1 (ru) * 2012-04-24 2013-09-10 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Способ оценки активности системы эксцизионной репарации нуклеотидов млекопитающих
ES2595240T3 (es) 2012-07-09 2016-12-28 Lupin Limited Derivados de tetrahidroquinazolinona como inhibidores de PARP
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
US10227610B2 (en) * 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
EP3052655B1 (en) 2013-09-30 2018-11-07 Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
WO2016028870A1 (en) * 2014-08-20 2016-02-25 Albert Einstein College Of Medicine, Inc. Methods and compositions for assessing germline risk of cancer
KR102531016B1 (ko) 2014-11-21 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
WO2016112177A1 (en) * 2015-01-08 2016-07-14 Yale University Novel Compositions Useful for Killing DNA Repair-Deficient Cancer Cells, and Methods Using Same
CN105985294B (zh) * 2015-02-11 2020-12-25 四川科伦药物研究院有限公司 一种奥拉帕尼的制备方法
RU2686317C2 (ru) * 2015-04-24 2019-04-25 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Замещенные 1,2,5-триметил- и 2,2,6,6-тетраметил-4-аминопиперидины, обладающие антиишемическим действием
WO2016185406A1 (en) 2015-05-19 2016-11-24 Nadathur Estates Pvt. Ltd. Method for identification of a deficient brca1 function
JP7539760B2 (ja) 2015-07-17 2024-08-26 パシレックス・ファーマシューティカルズ・インコーポレイテッド Ｎｍｔ２の後成的なサイレンシング
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN106699672B (zh) * 2015-11-16 2019-10-29 上海博邦医药科技有限公司 一种奥拉帕尼无定型物及其制备方法
JP7017509B2 (ja) * 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
RU2639535C2 (ru) * 2015-12-07 2017-12-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ скрининга противоопухолевых препаратов - ингибиторов parp1 на основе биохимических методов анализа
US10823738B2 (en) * 2015-12-07 2020-11-03 George Mason Research Foundation, Inc. Methods for breast cancer treatment
ITUB20159206A1 (it) 2015-12-22 2017-06-22 Olon Spa Forme cristalline e amorfe di olaparib
WO2017146947A1 (en) * 2016-02-22 2017-08-31 New York Intitute Of Technology Method for treating cancer by disabiling braca1/fancm interaction
CN113831407B (zh) 2016-05-20 2024-06-11 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
JP6682116B2 (ja) * 2016-06-02 2020-04-15 国立大学法人 長崎大学 ガン転移抑制剤
US12121518B2 (en) 2017-03-09 2024-10-22 The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College PARP-1 and methods of use thereof
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
CN107384916A (zh) * 2017-08-03 2017-11-24 中国科学院成都生物研究所 一种广谱性的癌症治疗基因靶点及其应用
US20200268864A1 (en) * 2017-10-25 2020-08-27 Jean Zhao Cancer vaccine compositions and methods for using same to treat cancer
WO2019133864A1 (en) 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US11149300B1 (en) * 2018-01-26 2021-10-19 Cedars-Sinai Medical Center Methods of treating gastrointestinal malignancies
CN112334133A (zh) 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
CA3099155A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
GB201913030D0 (en) * 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4072551A4 (en) * 2019-12-11 2023-11-15 Repare Therapeutics Inc. USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS
JP2023508357A (ja) 2019-12-23 2023-03-02 アキュター バイオテクノロジー インコーポレイテッド エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ
US20230119558A1 (en) * 2020-03-06 2023-04-20 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Dna damage repair genes in cancer
US20230234938A1 (en) 2020-04-28 2023-07-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2021225407A1 (ko) * 2020-05-08 2021-11-11 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도
US20230250145A1 (en) * 2020-06-24 2023-08-10 Moma Therapeutics, Inc. Compositions and methods for the treatment of cancer
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN114805263B (zh) * 2021-01-18 2023-05-05 四川大学 3-(羟基苄基)苯酞类化合物、其制备方法和用途
MX2023011241A (es) 2021-03-23 2023-10-03 Nuvation Bio Inc Compuestos dirigidos a receptores de hormonas nucleares contra el cancer.
WO2022204474A1 (en) * 2021-03-25 2022-09-29 The Trustees Of The University Of Pennsylvania Car-t delivery of synthetic peptide therapeutics
CN113024516B (zh) * 2021-03-29 2022-05-17 中国药科大学 双靶点parp/ezh2抑制剂、制备方法及用途
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase
JP2024516024A (ja) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
US12295960B2 (en) 2021-10-17 2025-05-13 University of South Alabama Foundation for Research and Commercialization Cancer treatment
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CA3257870A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. THIADIAZOLYL DERIVATIVES USED AS DNA POLYMERASE THETA INHIBITORS AND THEIR USES
CN115960018B (zh) * 2022-12-19 2024-01-05 湖南岳靶生物医药有限公司 一种egfr抑制剂、组合物及其应用
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
EP4506003A1 (en) 2023-08-07 2025-02-12 S.Yu Yunusov Institute of Chemistry of Plant Substances of the Academy of Sciences of the Republic of Uzbekistan Halogen derivatives of (4´,5´- methylenedioxyphenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline for use in the treatment of leukemia
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2707069A1 (de) * 1977-02-18 1978-08-24 Blaszczak Joseph W Polymerisationsprodukt von formaldehyd und kohlehydraten, verfahren zu seiner herstellung und arzneimittel
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5260195A (en) 1991-01-03 1993-11-09 Boehringer Mannheim Corporation Nonaqueous polymeric reagent compositions and applications thereof
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
ATE201445T1 (de) 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
ATE198623T1 (de) 1994-08-12 2001-01-15 Myriad Genetics Inc Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
US5908861A (en) 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
EP1183259A2 (de) 1999-09-28 2002-03-06 Basf Aktiengesellschaft Azepinoindol-derivate, deren herstellung und anwendung
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
GB9930519D0 (en) 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
DE50112961D1 (de) 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
AU2001245489A1 (en) * 2000-03-07 2001-09-17 Whitehead Institute For Biomedical Research Human single nucleotide polymorphisms
AU2001248748A1 (en) 2000-04-18 2001-10-30 Sumitomo Pharmaceuticals Company, Limited Substituted piperazine compounds
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2001090077A1 (en) 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
EP1309594B1 (fr) 2000-08-08 2004-12-15 Sanofi-Aventis Derives de benzimidazole, leur preparation et leur application en therapeutique
HU228960B1 (hu) * 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2326464A1 (en) * 2000-11-20 2002-05-20 Aldo Perrone Improved electrically operated paintball gun
CZ20032233A3 (cs) * 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
JPWO2002068407A1 (ja) 2001-02-28 2004-06-24 山之内製薬株式会社 ベンゾイミダゾール化合物
WO2002090334A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
US7072771B2 (en) 2001-06-07 2006-07-04 University Of Kentucky Research Foundation Selective PARP-1 targeting for designing chemo/radio sensitizing agents
US6644295B2 (en) * 2001-07-03 2003-11-11 Smart Parts, Inc. Pneumatic assembly for a paintball gun
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
US20030034020A1 (en) * 2001-08-14 2003-02-20 Mario Irizarry Components made of polymers with high luminous transmittance for compressed-gas-powered guns
WO2003051879A1 (en) 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7351530B1 (en) 2001-12-20 2008-04-01 Health Research, Inc. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
WO2003057145A2 (en) 2001-12-31 2003-07-17 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
AU2003211381B9 (en) 2002-02-19 2009-07-30 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
BR0307944A (pt) 2002-02-25 2005-02-01 Kudos Pharm Ltd Piranonas úteis como inibidores de atm
US6708685B2 (en) * 2002-03-06 2004-03-23 National Paintball Supply, Inc. Compressed gas-powered projectile accelerator
US7237545B2 (en) * 2002-03-06 2007-07-03 Aj Acquisition I Llc Compressed gas-powered projectile accelerator
US7886731B2 (en) * 2002-03-06 2011-02-15 Kee Action Sports I Llc Compressed gas gun having reduced breakaway-friction and high pressure dynamic separable seal flow control device
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
DE60335359D1 (de) * 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
AU2003253906A1 (en) 2002-07-19 2004-02-09 Osteotech, Inc. Chisels and procedure for insertion of spinal implant in a spinal disc space
US6732726B2 (en) * 2002-08-28 2004-05-11 Avalon Manufacturing Company Paint ball gun having a front mounted gas cylinder
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
GB0305681D0 (en) * 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7176188B2 (en) 2003-05-07 2007-02-13 UniversitéLaval Method of lethally sensitizing human and animal cells
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
US20050155591A1 (en) * 2003-12-29 2005-07-21 Glenn Forster Electronically controlled gas-powered guns for firing paintballs
US20060011185A1 (en) * 2004-06-18 2006-01-19 Npf Limited Paintball marker with an air balanced exhaust poppet valve with bias closure
US20060185657A1 (en) * 2005-02-24 2006-08-24 Stanley Gabrel Paintball gun with power assisted trigger

Also Published As

Publication number Publication date
TW200530196A (en) 2005-09-16
AU2004294790B2 (en) 2010-03-11
US20120135983A1 (en) 2012-05-31
ES2371469T3 (es) 2012-01-03
EP1684736B1 (en) 2011-08-24
IL176013A0 (en) 2006-10-05
US20050227919A1 (en) 2005-10-13
DK1684736T3 (da) 2011-11-21
JP5545690B2 (ja) 2014-07-09
JP2007516241A (ja) 2007-06-21
US20240245643A1 (en) 2024-07-25
HK1089358A1 (en) 2006-12-01
NO335959B1 (no) 2015-03-30
AU2010202197B2 (en) 2013-05-23
PT2305221E (pt) 2015-09-03
SG150548A1 (en) 2009-03-30
PT1684736E (pt) 2011-11-10
AU2010202197A1 (en) 2010-06-17
HUE025996T2 (en) 2016-05-30
NO20063078L (no) 2006-08-28
ATE521341T1 (de) 2011-09-15
CN102107008B (zh) 2013-04-03
RU2755865C2 (ru) 2021-09-22
TWI338000B (en) 2011-03-01
RU2413515C2 (ru) 2011-03-10
US8071579B2 (en) 2011-12-06
AU2004294790A1 (en) 2005-06-16
CN102107008A (zh) 2011-06-29
ES2545613T3 (es) 2015-09-14
WO2005053662A1 (en) 2005-06-16
JP5545772B2 (ja) 2014-07-09
PL1684736T3 (pl) 2012-01-31
RU2017101713A3 (https=) 2020-02-17
US20060142231A1 (en) 2006-06-29
EP2305221B1 (en) 2015-05-20
CA2547077A1 (en) 2005-06-16
JP2012067092A (ja) 2012-04-05
EP2305221A1 (en) 2011-04-06
MXPA06006120A (es) 2007-04-16
NZ547984A (en) 2009-03-31
US8143241B2 (en) 2012-03-27
CA2547077C (en) 2015-11-03
US20210244706A1 (en) 2021-08-12
DK2305221T3 (en) 2015-08-24
EP1684736A1 (en) 2006-08-02
US20170319543A1 (en) 2017-11-09
RU2006121459A (ru) 2008-01-10
KR20060123403A (ko) 2006-12-01
RU2017101713A (ru) 2018-07-19
BRPI0417056A (pt) 2007-02-06
IL176013A (en) 2015-10-29
RU2010149166A (ru) 2012-06-10

Similar Documents

Publication Publication Date Title
SG150548A1 (en) Dna damage repair inhibitors for treatment of cancer
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
MXPA05013822A (es) Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer.
WO2005034845A3 (en) Compositions and methods for treatment of cancer
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
AU2003265556A8 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
MXPA05013549A (es) Derivados de tienopirimidina como inhibidores del canal de potasio.
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2007059008A3 (en) N-substituted indenoisoquinolines and syntheses thereof
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
BRPI0416994A (pt) inibidores de proteìna cinase com base em indolinona avançada
WO2006015191A3 (en) Multicyclic lonidamine analogs
WO2006113579A3 (en) Tumor inhibition by modulating sprouty expression or activity
WO2005089730A3 (en) Dna pkinase inhibitors for treating cancer and diabetes
WO2005054183A3 (en) Quinolinone based protein kinase inhibitors
WO2005082357A8 (en) Use of beta-lapachone for treating hematologic tumors
WO2004019959A3 (en) Dna repair enzymes
WO2006109091A3 (en) Sensitisation of cancer cells to dna replication inhibitors
HK1108318A (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2004026242A3 (en) Substituted ketophosphonate inhibitors of tumor cell proliferation